Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...

Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

ICU Medical (ICUI) and Otsuka are launching a joint venture focused on boosting IV solutions production and development in North America. Read more here.

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

Recent quality and operational issues at Smiths, which originated before it was purchased, greatly reduced ICU’s gross margin after the acquisition. These issues have required additional spending to ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, ...

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Pharmaceutical Factory America, a subsidiary of Otsuka Pharmaceutical Factory, has ...

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional ...